摘要
Background: Chimeric antigen receptor T cell (CAR-T) therapy has achieved remarkable effects in refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). However, many patients receiving CAR-T therapy still eventually die of disease recurrence or progression due to target antigen loss or exhaustion of CAR-T cells. Therefore, maintaining the efficacy of CAR-T has become a particular research focus. As lenalidomide can regulate T cell function, we conducted a study to evaluate the efficacy of lenalidomide maintenance after CAR-T therapy in R/R DLBCL patients. @@@ Methods: Seven R/R DLBCL patients who received lenalidomide maintenance after CAR-T therapy and nine DLBCL patients that underwent CAR-T treatment alone were included. The clinical data of all subjects were collected to evaluate the efficacy of lenalidomide maintenance. In order to understand the possible mechanisms of lenalidomide in CAR-T therapy, CAR-T copies of peripheral blood were regularly detected by quantitative real-time polymerase chain reaction, and an in vitro test was also conducted. @@@ Results: Overall survival (OS) was significantly prolonged in the lenalidomide maintenance group. Furthermore, one case responding to CAR-T therapy initially but suffering a relapse shortly achieved complete remission again after lenalidomide exposure, with an increase in the number of CAR-T copies detected. The in vitro test showed that lenalidomide could delay the exhaustion of CAR-T cells. @@@ Conclusions: Lenalidomide maintenance after CAR-T therapy is a safe and effective choice for R/R DLBCL patients. We confirmed that lenalidomide maintenance can improve patients' OS, and the delayed exhaustion of CAR-T cells may contribute to this OS benefit.
学科与关键词
- Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patientsQu, Changju*; Zou, Rui; Wang, Peng; Zhu, Qian; Kang, Liqing; Ping, Nana; Xia, Fan; Liu, Hailing; Kong, Danqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*Frontiers in Immunology, 2022, 13: 969660.被引 8
- CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphomaCheng, Qian; Tan, Jingwen; Liu, Rui; Kang, Liqing; Zhang, Yi; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Xu, Nan; Li, Minghao; Yu, Lei*; Li, Xin*CYTOTHERAPY, 2022, 24(10): 1026-1034.被引 9
- The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell LymphomaWei, Xiaolei; Guo, Xutao; Wei, Qi; Xiong, Dan; Zhang, Peng; Zhang, Zewen; Wei, Yongqiang; Feng, Ru65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
